InMed Pharmaceuticals (INM) Net Cash Flow (2019 - 2026)

InMed Pharmaceuticals has reported Net Cash Flow for 8 years, with the latest figure at -$1.5 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 216.11% year-over-year to -$1.5 million in Q1 2026; TTM through Mar 2026 was $811547.0, a 127.79% increase from a year earlier, with the FY2025 full-year figure at $4.5 million, up 292.42% from the prior year.
• Net Cash Flow was -$1.5 million for Q1 2026 at InMed Pharmaceuticals, up from -$2.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $6.4 million in Q2 2025, with the low at -$5.4 million in Q1 2022.
• Average Net Cash Flow over 5 years is -$584314.2, with a median of -$1.5 million recorded in 2026.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 849.58% in 2022, then jumped 721.59% in 2025.
• Over 5 years, Net Cash Flow stood at $2.6 million in 2022, then sank by 171.02% to -$1.8 million in 2023, then retreated by 17.07% to -$2.2 million in 2024, then retreated by 9.83% to -$2.4 million in 2025, then soared by 38.41% to -$1.5 million in 2026.
• The last three Net Cash Flow figures came in at -$1.5 million (Q1 2026), -$2.4 million (Q4 2025), and -$1.7 million (Q3 2025), per Business Quant data.